Tomorrow UCB will publish her past quarter's results. Based on the analyst expectation both the revenue and the net profit would be on all time high levels. For this year most of the analyst expect a total sales of 4,06 billion euros. The expectations would mean a record revenue for the company. This is slightly more than the 2015's revenue of 3,88 billion euros.
For 2016 the analysts expect a record net profit of 540 million euros. For this year the analyst's consensus of UCB 's result per share is a profit of 2,88 euros. Based on the analyst's expectations the price/earnings-ratio is 23,27.Per share a dividend of 1,26 euros is expected. The dividend return consequently equals 1,88 percent. The average dividend of the pharmaceutical company equals 0,41 percent.
The stock UCB is being covered by 13 fundamental analysts. The average target price for the stock is at 80,64 euros. This is around 20 percent more than the current stock price of 67,02 euros. HSBC , JP Morgan and Berenberg recently provided recommendations for the company.
Based on the number of outstanding shares UCB 's market capitalization equals 12,62 billion euros.The stock traded at 11.10 0,81 percent lower at 67,02 euros.
ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.